CytoImmune Therapeutics
Founded 2019
About CytoImmune Therapeutics
CytoImmune Therapeutics develops novel, coordinated immunotherapy solutions for patients. Their CoalesceNT platform harnesses the power of bispecific antibody (biAb) and chimeric antigen receptor (CAR) technology to coordinate an immune response with both natural killer (NK) and T cells. This combination of NK- and T-cell therapy expedites time-to-treatment and delivers a dynamic immune response that reflects natural immunity.
Company Facts
- Founded: 2019
- Legal name: CytoImmune Therapeutics, Inc.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Website: cytoimmune.com
- Phone: 4692222350
Social Profiles
Canonical: https://fsome.com/organization/cytoimmune-therapeutics-8451300 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.